Journal
PEPTIDES
Volume 31, Issue 4, Pages 736-756Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2009.12.015
Keywords
Depression; Anxiety; Stress; Animal models; Corticotropin-releasing factor; Urocortin; Teneurin; Neuropeptide Y; Vasopressin; Oxytocin; Tyr-MIF-1; Cholecystokinin; Galanin; Substance P; Receptor antagonists
Funding
- Canadian Institutes of Health Research (CIHR) [FRN: 7202762]
- Natural Sciences and Engineering Research Council of Canada (NSERC) f
Ask authors/readers for more resources
In recent years, studies have advocated neuropeptide systems as modulators for the behavioral states found in mood disorders such as depression and anxiety disorders. Neuropeptides have been tested in traditional animal models and screening procedures that have been validated by known antidepressants and anxiolytics. However, it has become clear that although these tests are very useful, neuropeptides have distinct behavioral effects and dose-dependent characteristics, and therefore, use of these tests with neuropeptides must be done with an understanding of their unique characteristics. This review will focus on the behavioral actions of neuropeptides and their synthetic analogs, particularly in studies utilizing various preclinical tests of depression and anxiety. Specifically, the following neuropeptide systems will be reviewed: corticotropin-releasing factor (CRF), urocortin (Ucn), teneurin C-terminal associated peptide (TCAP), neuropeptide Y (NPY), arginine vasopressin (AVP), oxytocin, the Tyr-MIF-1 family, cholecystokinin (CCK), galanin, and substance P. These neuropeptide systems each have a unique role in the regulation of stress-like behavior, and therefore provide intriguing therapeutic targets for mood disorder treatment. (C) 2010 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available